Accumulate Divi’s Laboratories; target of Rs 3931: KR Choksey

KR Choksey recommended accumulate rating on Divi’s Laboratories with a target price of Rs 3931 in its research report dated April 03, 2024.

Broker Research

April 04, 2024 / 02:19 IST

Accumulate

26 Aug, 2025 12:21

Volume

Todays L/H

KR Choksey's research report on Divi’s Laboratories

Divi’s Laboratories Limited (DIVISLAB), founded in 1990 and headquartered in Hyderabad (India) is one of the largest manufacturers and suppliers of Active Pharma Ingredients (APIs) and intermediates for global innovator companies, with a presence in over 100 countries. It is positioned as one of the two largest generic API manufacturers in the world for 10 out of 30 generic APIs it manufactures. It also offers custom synthesis (contract development and manufacturing organization - CDMO) of APIs and nutraceuticals ingredients with overall product portfolio of over 160 products across cardiovascular, antiinflammatory, anti-cancer, and central nervous system (CNS) therapy areas. Within nutraceuticals segment, the company manufactures active ingredients, and finished forms of Carotenoids, Lutein, and vitamins. The company is a major supplier of carotenoids to a host of major food, dietary supplement, and feed manufacturing worldwide. The company has 2 manufacturing plants located in Hyderabad and Andhra Pradesh, India.

Outlook

We expect DIVISLABS to grow the revenue and earnings at 9.0% and 28.0% CAGR, respectively over FY24E-FY26E. The stock has traded historically at a 1-year forward PE of 47.5x during its peak profitable years during FY21-FY22. Currently, it is trading at 52.7x/61.0x/45.8x/37.4x its FY23/FY24E/FY25E/FY26E EPS. We value it at 40.6x its FY26E EPS of Rs. 96.8 and arrive at a Target price (TP) of Rs. 3,931. We initiate coverage on DIVISLABS with an ACCUMULATE rating as TP implies a 9% upside from current levels.